Current status and future direction in the management of malignant melanoma

被引:45
|
作者
Gladfelter, Patrick [1 ]
Darwish, Noureldien H. E. [1 ,2 ]
Mousa, Shaker A. [1 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY USA
[2] Mansoura Univ, Dept Clin Pathol, Fac Med, Mansoura, Egypt
关键词
BRAF; CTLA-4; MEK inhibitor; melanoma; nanoparticle; programmed cell death 1 receptor; photodynamic therapy; PHASE-II TRIAL; METASTATIC MELANOMA; OPEN-LABEL; PHOTODYNAMIC THERAPY; FEEDBACK INHIBITION; CUTANEOUS MELANOMA; IMPROVED SURVIVAL; TARGETED THERAPY; ADJUVANT THERAPY; BRAF-MUTANT;
D O I
10.1097/CMR.0000000000000379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incidence of malignant melanoma is increasing rapidly on a global scale. Although some types of melanoma, for example primary cutaneous melanoma, can be managed by surgery, metastatic melanoma cannot and it has a high mortality rate. Both oncogene and immune-targeted strategies have shown marked efficacy in some patients, but their effect on overall survival is still variable. Therefore, newer therapeutic approaches are needed. Fortunately, new advances in molecular medicine have led to an understanding of an individual patient's cancer at the genomic level. This information is now being used in all stages of cancer treatment including diagnosis, treatment selection, and treatment monitoring. This new strategy of personalized medicine may lead to marked shifts in immunotherapeutic treatment approaches such as individualized cancer vaccines and adoptive transfer of genetically modified T cells. This review provides an overview of recent approaches in cancer research and expected impact on the future of treatment for metastatic melanoma. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 50 条
  • [1] Cilengitide Treatment for Malignant Glioma: Current Status and Future Direction
    Kurozumi, Kazuhiko
    Ichikawa, Tomotsugu
    Onishi, Manabu
    Fujii, Kentaro
    Date, Isao
    [J]. NEUROLOGIA MEDICO-CHIRURGICA, 2012, 52 (08) : 539 - 547
  • [2] Prehospital Pain Management: Current Status and Future Direction
    Hennes, Halim
    Kim, Michael K.
    [J]. CLINICAL PEDIATRIC EMERGENCY MEDICINE, 2006, 7 (01) : 25 - 30
  • [3] The current status and future direction of percutaneous peptide immunization against melanoma
    Seo, Naohiro
    Takigawa, Masahiro
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2007, 48 (02) : 77 - 85
  • [4] Editorial: Molecular Genetics of Cutaneous Melanoma: Current Status and Future Direction
    Pellegrini, Cristina
    Garcia-Casado, Zaida
    Cho, William C. C.
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [5] ETOPOSIDE - CURRENT STATUS AND FUTURE PERSPECTIVES IN THE MANAGEMENT OF MALIGNANT NEOPLASMS
    BELANI, CP
    DOYLE, LA
    AISNER, J
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 : S118 - S126
  • [6] Hazardous industrial waste management in Vietnam: current status and future direction
    Nguyen Thi Kim Thai
    [J]. Journal of Material Cycles and Waste Management, 2009, 11 : 258 - 262
  • [7] Hazardous industrial waste management in Vietnam: current status and future direction
    Thai, Nguyen Thi Kim
    [J]. JOURNAL OF MATERIAL CYCLES AND WASTE MANAGEMENT, 2009, 11 (03) : 258 - 262
  • [8] Current status and future direction of community-based management of hypertension in China
    Sun, Yingxian
    Sun, Guozhe
    Chang, Ye
    [J]. JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2021, 9 (02) : 61 - 64
  • [9] CURRENT MANAGEMENT OF MALIGNANT-MELANOMA
    MORTON, DL
    [J]. ANNALS OF SURGERY, 1990, 212 (02) : 123 - 124
  • [10] CURRENT MANAGEMENT OF MALIGNANT-MELANOMA
    COIT, DG
    BRENNAN, MF
    [J]. SURGERY, 1993, 113 (02) : 128 - 129